U.S. Issues Patent for Administration of Pentec Health’s PROPLETE® Product

Share Article

Latest Award Extends Patent Protection to Domestic IDPN Market

Pentec Health, Inc. today announced that its proprietary PROPLETE® product line has been awarded a United States patent. The renal nutrition formulation now enjoys patent protection in the US, as well as Europe (United Kingdom), Asia (Japan, Hong Kong), Australia (Australia, New Zealand), Africa (South Africa) and North America (Canada). It is the only Intradialytic Parenteral Nutrition formulation in the US with a patent.

"With the award of a US patent, Proplete patents now literally circle the globe,” remarked Joseph Cosgrove, Chairman, President and CEO of Pentec Health. “The US patent has been long anticipated by our employees and associates across the country,” noted Cosgrove. “The issuance of the only American patent for administration of an IDPN nutritional supplement recognizes the uniquely distinctive profile of this widely utilized therapy. It provides yet another source of pride for the entire Pentec Health family.”

The PROPLETE® product line, Pentec Health's proprietary Intradialytic Parenteral Nutrition (IDPN) supplement, was developed through continued efforts to meet the renal nutrition needs of the dialysis community. The PROPLETE® product line is effective in treating patients with malnutrition who are receiving hemodialysis for end-stage chronic kidney disease.

The inventor, Eileen Moore, CNSC, RD LD, Clinical Liaison Director-Renal Products at Pentec Health explains, “The formulation design addresses the issue of protein malnutrition and, unlike traditional products, is characterized by reduced dextrose, no lipids and low volume.” She adds, “It is noteworthy that the use of PROPLETE® IDPN therapy demonstrated an increase in albumin levels of both non-diabetic and diabetic hemodialysis patients. According to key opinion leaders, improved albumin levels coupled with an improving protein energy wasting profile have demonstrated a potential for not only a higher quality of life but also for survival advantages for patients.” As of December 31, 2012, there were nearly a half million prevalent hemodialysis patients in the US, nearly half of which had a diagnosis of diabetes. References available upon request.

Not surprisingly and buoyed by this latest success, Pentec Health is currently pursuing additional patents for its PROPLETE® product line in the US and around the world. Pentec's PROPLETE® and pharmacy compounding services are available in all 50 US states.

About Pentec Health, Inc.
For over 30 years, Pentec Health has been an industry leader in providing physician prescribed, custom prepared, patient-specific sterile medications that are intended for patient administration in the home as well as various alternate administration sites. Pentec Health is focused on providing renal nutritional products and services to dialysis centers for their malnourished dialysis patients, and as a Joint Commission accredited home care provider, the company offers in-home infusion services for highly complex conditions that are underserved by traditional home care providers. For more information on Pentec Health, Inc., visit http://www.pentechealth.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Monique Costa
+1 (856) 906-7833
Email >

Janet Garrett
Visit website